文献速递肿瘤 PET/CT

靶向纤连蛋白额外结构域A以改进三阴性乳腺癌的无创检测

Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
PubMed 文献 · J Nucl Med · 2025-06-02

本研究以纤连蛋白额外结构域A(EDA-FN)为靶点,用单克隆抗体F8构建[89Zr]Zr-DFO-F8探针,在多种临床前三阴性乳腺癌(TNBC)异种移植模型中行PET/CT检测。体外显示[89Zr]Zr-DFO-F8具有特异性、可阻断的EDA-FN结合活性,体内显示高肿瘤摄取,可检出皮下与原位TNBC异种移植瘤中的EDA-FN,并在侵袭性疾病中与EDA-FN表达一致蓄积。

要点

  • 靶向EDA-FN的[89Zr]Zr-DFO-F8在体外显示特异性、可阻断的结合活性。
  • 在临床前TNBC异种移植模型中,[89Zr]Zr-DFO-F8显示高肿瘤摄取。
  • 该探针可检出皮下及原位TNBC异种移植瘤的EDA-FN,并勾勒多种分子亚型肿瘤。

核心结论

  • 作者认为,[89Zr]Zr-DFO-F8的EDA-FN成像在临床前TNBC多种分子亚型体内肿瘤勾勒中显示出强大的 delineation 能力。

研究设计与样本

  • 本研究为临床前研究,合成[89Zr]Zr-DFO-F8并在体外及体内评价其EDA-FN结合能力,在多种TNBC异种移植模型中行PET/CT检测。

主要发现

  • 体外实验显示[89Zr]Zr-DFO-F8具有特异性、可阻断的EDA-FN结合活性。
  • 体内实验显示在临床前TNBC异种移植模型中高肿瘤摄取。
  • [89Zr]Zr-DFO-F8可检出皮下及原位TNBC异种移植瘤中的EDA-FN,并在侵袭性疾病中与EDA-FN表达一致蓄积。

关键数值与推荐

  • [89Zr]Zr-DFO-F8在体外显示特异性、可阻断的EDA-FN结合活性。
  • 在临床前TNBC异种移植模型中观察到高肿瘤摄取。
  • [89Zr]Zr-DFO-F8可检出皮下及原位TNBC异种移植瘤的EDA-FN,并在侵袭性疾病中与EDA-FN表达一致蓄积。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triple-negative breast cancer (TNBC) lags behind other breast cancer types in targeted therapeutic and diagnostic imaging agent development, largely due to high disease heterogeneity. Noninvasive imaging is essential for diagnosing and staging TNBC and predicting and measuring treatment response. This study targeted a conserved disease-specific extracellular matrix protein domain (the extra domain A of fibronectin [EDA-FN]), with a monoclonal antibody (F8) to overcome tumor cell marker heterogeneity and develop an imaging agent to detect multiple TNBC subtypes and improve diagnostic capacity. Methods: [89Zr]Zr-desferrioxamine [DFO]-F8 was synthesized and evaluated in vitro and in vivo for EDA-FN binding capacity to detect TNBC by PET/CT in several preclinical xenograft models. Results: [89Zr]Zr-DFO-F8 exhibited specific, blockable EDA-FN binding activity in vitro. In vivo experiments demonstrated high tumor uptake in preclinical TNBC xenograft models. [89Zr]Zr-DFO-F8 detected EDA-FN in subcutaneous and orthotopic TNBC xenografts and accumulated in aggressive disease concordantly with EDA-FN expression. Conclusion: EDA-FN imaging with [89Zr]Zr-DFO-F8 exhibits powerful tumor delineation in preclinical tumor delineation across TNBC molecular subtypes in vivo.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hachey JS, Viray TD, Matasci M, et al. Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer. J Nucl Med. 2025. PMID: 40246542. doi:10.2967/jnumed.124.268859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。